Sign in / Join Now
ETFs & Funds
-Cellceutix Selects Dr. Reddy's Labs For Formulation of Brilacidin for Ophthalmic & Otitis Infections -
Add a reply...
Latest StockTalks »
people get CTIX breaking news and analysis by email alert.
Get email alerts on CTIX »
Get latest price
From other sites
Cellceutix Phase 2 Trial Initial Data Shows Potential Of Brilacidin As A Novel Anti-Inflammatory Drug Candidate For The Induction Of Remission Of Mild-to-Moderate Ulcerative Colitis
at TheStreet (Oct 10, 2016)
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial
at Benzinga.com (Dec 22, 2014)
Syracuse's Boeheim is taking basketball 'virtual'
at CNBC.com (Oct 3, 2014)